1. LPD-3 as a megaprotein brake for aging and insulin-mTOR signaling in C. elegans.
- Author
-
Pandey, Taruna, Pandey, Taruna, Wang, Bingying, Wang, Changnan, Zu, Jenny, Deng, Huichao, Shen, Kang, do Vale, Goncalo, McDonald, Jeffrey, Ma, Dengke, Pandey, Taruna, Pandey, Taruna, Wang, Bingying, Wang, Changnan, Zu, Jenny, Deng, Huichao, Shen, Kang, do Vale, Goncalo, McDonald, Jeffrey, and Ma, Dengke
- Abstract
Insulin-mechanistic target of rapamycin (mTOR) signaling drives anabolic growth during organismal development; its late-life dysregulation contributes to aging and limits lifespans. Age-related regulatory mechanisms and functional consequences of insulin-mTOR remain incompletely understood. Here, we identify LPD-3 as a megaprotein that orchestrates the tempo of insulin-mTOR signaling during C. elegans aging. We find that an agonist insulin, INS-7, is drastically overproduced from early life and shortens lifespan in lpd-3 mutants. LPD-3 forms a bridge-like tunnel megaprotein to facilitate non-vesicular cellular lipid trafficking. Lipidomic profiling reveals increased hexaceramide species in lpd-3 mutants, accompanied by up-regulation of hexaceramide biosynthetic enzymes, including HYL-1. Reducing the abundance of HYL-1, insulin receptor/DAF-2 or mTOR/LET-363, normalizes INS-7 levels and rescues the lifespan of lpd-3 mutants. LPD-3 antagonizes SINH-1, a key mTORC2 component, and decreases expression with age. We propose that LPD-3 acts as a megaprotein brake for organismal aging and that its age-dependent decline restricts lifespan through the sphingolipid-hexaceramide and insulin-mTOR pathways.
- Published
- 2024